Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04878263
Other study ID # 2019-CHITS-04
Secondary ID 2020-A02939-30
Status Completed
Phase N/A
First received
Last updated
Start date June 28, 2021
Est. completion date December 14, 2023

Study information

Verified date March 2024
Source Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute heart failure current management turns out to be a relative failure considering its elevated economical and human costs and the poor results obtained in terms of disease outcome. Indeed this disease remains associated with a high rate of early re-hospitalizations and low adherence to therapeutic recommended settings and doses. Moreover, extra cardiological follow-up such as in social, geriatric or vaccination fields remain low compared to real needs. Current recommendations incite health professionals to better define care pathways and to rationalize resources. Guidelines toward creation of hospitalization alternatives or limitation of time spent in hospital are given. In the same time, lack of cardiologic care management within heart failure patient care pathway is associated to poor prognosis and medical desertification as well as resource concentration on important health centers exacerbate this phenomenon. Innovative projects are then needed to improve patient care pathways, to open up areas without specialized health professionals and to rationalize care management by encouraging communication and skill exchange between hospitals and private practices. FIL-EAS ic projet aims to compare a conventional care pathway in hospital with a follow up defined according to High Authority of Health recommendations to an organized care pathway favoring a short hospitalization (maximum of 4 working days) with early transition, when possible, to a medical and paramedical home care management with an approximately 10 day long combined follow up between hospital and private practices. This second care pathway should help to optimize therapeutics in home living conditions.


Description:

Acute heart failure current management turns out to be a relative failure considering its elevated economical and human costs and the poor results obtained in terms of disease outcome. Indeed this disease remains associated with a high rate of early re-hospitalizations and low adherence to therapeutic recommended settings and doses. Current recommendations incite health professionals to better define care pathways and to rationalize resources. FIL-EAS ic projet aims to compare a conventional care pathway in hospital with a follow up defined according to High Authority of Health recommendations to an organized care pathway favoring a short hospitalization (maximum of 4 working days) with early transition, when possible, to a medical and paramedical home care management with an approximately 10 day long combined follow up between hospital and private practices. Patients included in the study will be followed up for 6 months with one phone contact one month after hospital discharge, a second one two months later and one consultation 6 months after inclusion in the study.


Recruitment information / eligibility

Status Completed
Enrollment 361
Est. completion date December 14, 2023
Est. primary completion date December 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient over 18 years old hospitalized for acute heart failure - Patient able to express his consent before participating in the study, certified by the caregiver if a written consent is not possible - Patient able to follow protocol procedures, alone or with a caregiver help - Caregiver consent to participate in the study and assist the patient during its own participation, if caregiver involvement is necessary - Patient requiring an hospitalisation of at least 24 hours - Patient covered by social security or equivalent regimen - Patient having access to a mobile of fixed phone line Exclusion Criteria: - Admission in intensive care or resuscitation unit AND need for inotropic support, vasodilator, or invasive/non-invasive ventilation for the last 24h - Renal insufficiency with CKD-EPI clearance inferior to 15 ml/min/1.73m2 since admission or dialysis - Patient planned transfer to a rehabilitation and recuperative care facility (hospital or nursing home) - Associated disease requiring frequent re-hospitalizations (cancer, dialysis, repeated sessions during planned hospitalizations) - Associated disease with a high risk of death for the next 6 months - Chronical respiratory insufficiency requiring daily invasive ventilation or a more than 3L/min permanent oxygen therapy - Patient suffering from severe dementia defined by a MMSE score = 9 - Person participating in another research testing another care pathway - Every other reason which, according to investigator, might interfere with study objective assessment - Person under judicial protection measure (guardianship, curatorship) - Person deprived of liberty by a judicial or administrative decision

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Conventional hospitalization
Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
FIL-EAS ic care pathway
Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.

Locations

Country Name City State
France Centre Hospitalier Intercommunal Toulon La Seyne sur Mer Toulon Var
France Hôpital Sainte Anne Toulon Var

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer French Cardiology Society

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary FIL-EAS ic care pathway safety non inferiority Safety non inferiority will be assessed by comparing the proportion of patients deceased or with unplanned re-hospitalizations for heart failure within the 6 months following randomization between FIL-EAS ic care pathway and conventional hospitalization. 6 months
Secondary FIL-EAS ic care pathway safety superiority Safety superiority will be assessed by comparing the proportion of patients deceased or with unplanned re-hospitalizations for heart failure within the 6 months following randomization between FIL-EAS ic care pathway and conventional hospitalization. 6 months
Secondary Quality of life assessed by EQ-5D questionnaire Scores obtained after EQ-5D questionnaire completion will be collected during inclusion and research end visit. Evolution between these two scores will be compared between FIL-EAS ic care pathway and conventional hospitalization. EQ-5D questionnaire assess through 5 questions patient mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels : no problems, slight, moderate, severe and finally extreme problems. The patient is asked to tick the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The questionnaire records also patient's self-rated health on a vertical visual analogue scale going from 0 to 100. 0 corresponds to 'The worst health you can imagine' and 100 to 'The best health you can imagine'. 6 months
Secondary Satisfaction assessed by QSH-37 questionnaire Scores obtained after QSH-37 questionnaire completion will be collected during the visit performed at the end of initial hospitalization and compared between FIL-EAS ic care pathway and conventional hospitalization. The QSH-37 is composed of 37 questions about care management throughout patient hospitalization from the admission until patient's discharge and concerns following elements : relation with professionals (doctors, nurses, housekeepers), response delays, cleanliness, food and room equipment. For each item, possible answers go from "better than desired" to "extremely less than desired". At the moment of patient initial discharge, up to 3 weeks
Secondary Cumulative number of days spent in hospital The cumulative number of days spent in hospital within the 6 months following randomization will be compared between FIL-EAS ic care pathway and conventional hospitalization. In this calculation will be taken into account hospitalizations for acute care, hospitalizations for serious illnesses during their acute phases, mental health activities and non-ambulatory follow-up care and rehabilitation unit stays. 6 months
Secondary Impact on medical recommendation compliance Rate of prescription with percentage of recommended dose of heart failure treatments will be collected and compared between the two groups at initial hospitalization discharge and 6 months after. Rate of influenza, pneumococcal and Covid-19 vaccination, percentage of home therapeutic education use, percentage of ambulatory cardiovascular re-education use and rate of acute renal insufficiency occurrence during initial hospitalization will also be assessed. 6 months
Secondary Geriatric evolution throughout care pathway Scores obtained at 5 questionnaires will be collected during inclusion visit and research end visit. The evolution of these scores between these two time points will be compared between FIL-EAS ic care pathway and conventional hospitalization. These 5 questionnaires are : ADL (Activities of Daily Leaving), IADL(Instrumental Activities of Daily Leaving)-LAWTON, MNA (Mini Nutritional Assessment), mini GDS (Geriatric Depression Scale) and Dubois 5 words test. The two first asses the ability to perform daily activities. The third one aims at detecting malnutrition cases and is composed of 18 questions. Mini GDS, composed of 4 questions, detects depression cases and finally Dubois 5 words test is a tool evaluating patient cognitive functions. Besides these questionnaires, percentage of geriatric consultation occurrence throughout study participation will be compared between the two care pathways. 6 months
Secondary Predictive value of biological analyses Biological analyses results performed throughout study participation will be compared between FIL-EAS ic care pathway and conventional hospitalization and their predictive value with respect to the occurrence of unplanned re-hospitalizations for heart failure or deaths will be evaluated. 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04080388 - How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study) Phase 3
Recruiting NCT04751838 - Development and Validation of a Simple-to-use Nomogram for Predicting In-hospital Mortality in Acute Heart Failure Patients Undergoing Continuous Renal Replacement Therapy
Active, not recruiting NCT04618601 - Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure Phase 4
Recruiting NCT06142474 - SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning Phase 3
Active, not recruiting NCT05603247 - The SWISSHEART Failure Network (SHFN)
Recruiting NCT03169803 - Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) N/A
Not yet recruiting NCT06273397 - Acetazolamide or Metolazone in Acute Heart Failure N/A
Recruiting NCT03542123 - Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects N/A
Not yet recruiting NCT06442280 - SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF Phase 4
Completed NCT04281849 - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program N/A
Not yet recruiting NCT04403659 - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study N/A
Terminated NCT03574857 - Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Phase 4
Completed NCT03136198 - B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial Phase 2
Terminated NCT03746002 - Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing Phase 4
Active, not recruiting NCT03513653 - Strain for Risk Assessment and Therapeutic Strategies in Patients With Acute Heart Failure (STRATS-AHF) Registry
Recruiting NCT06092437 - Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients N/A
Recruiting NCT05746923 - Lesser Poland Cracovian Heart Failure Registry
Recruiting NCT06414928 - Prognostic Model Heart Failure
Completed NCT04606927 - Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure N/A
Completed NCT03200860 - Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure Phase 2